Podrobno

Strategije preživetja starostnikov z nizkimi pokojninami : magistrsko delo
ID Rupnik, Nika (Avtor), ID Tivadar, Blanka (Mentor) Več o mentorju... Povezava se odpre v novem oknu

URLURL - Predstavitvena datoteka, za dostop obiščite http://dk.fdv.uni-lj.si/magistrska_dela_2/pdfs/mb22_rupnik-nika.pdf Povezava se odpre v novem oknu

Jezik:Slovenski jezik
Vrsta gradiva:Magistrsko delo/naloga
Tipologija:2.09 - Magistrsko delo
Organizacija:FDV - Fakulteta za družbene vede
Kraj izida:Ljubljana
Založnik:[N. Rupnik]
Leto izida:2011
Št. strani:58 str.
PID:20.500.12556/RUL-19859 Povezava se odpre v novem oknu
UDK:368.914-053.9(043.2)
COBISS.SI-ID:30951773 Povezava se odpre v novem oknu
Datum objave v RUL:11.07.2014
Število ogledov:4127
Število prenosov:196
Metapodatki:XML DC-XML DC-RDF
:
RUPNIK, Nika, 2011, Strategije preživetja starostnikov z nizkimi pokojninami : magistrsko delo [na spletu]. Magistrsko delo. Ljubljana : N. Rupnik. [Dostopano 25 marec 2025]. Pridobljeno s: http://dk.fdv.uni-lj.si/magistrska_dela_2/pdfs/mb22_rupnik-nika.pdf
Kopiraj citat
Objavi na:Bookmark and Share

Podobna dela

Podobna dela v RUL:
  1. ǂThe ǂimportance of cancer stem cells and epithelial-mesenchymal transition in the progression of non-small cell lung cancer
  2. Gene expression levels of the prolyl hydroxylase domain proteins PHD1 and PHD2 but not PHD3 are decreased in primary tumours and correlate with poor prognosis of patients with surgically resected non-small-cell lung cancer
  3. Study of phosphatidylethanolamine N-methyltransferase gene expression in non-small cell lung cancer tissue
  4. Usefulness of immunohistochemically determined epidermal growth factor receptor mutations in lung cancer
  5. Diabetes mellitus and physical activity
Podobna dela v drugih slovenskih zbirkah:
  1. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small cell lung cancer
  2. Outsourcing predictive biomarker testing in non-small cell carcinoma
  3. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  4. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  5. NSCLC molecular testing in Central and Eastern European countries

Nazaj